Dr Russell Basser is a qualified physician and spent 10 years in an academic clinic Medical Oncology/Haematology. Since joining CSL (a leading biopharmaceutical company specialising in plasma-derived, recombinant protein therapeutics and influenza vaccines) in 2001, he has worked in a wide range of therapeutic areas and overseen clinical development, clinical operations, regulatory affairs, drug safety and biometrics/medical writing. He was responsible for globalising the Clinical R&D group and rebuilding the development capabilities in Japan and in 2014 was appointed to the role of Chief Medical Officer in Melbourne, Australia. He recently took up the role of SVP R&D at Seqirus (a fully owned subsidiary of CSL Ltd), a new specialist influenza vaccine company formed from the merger of bioCSL which acquired influenza vaccine assets of Novartis. Seqirus is the second largest influenza vaccine company globally.